Melanotan 1 (MT1) Dosing: What Clinics Prescribe and What to Expect (2026)
Key Takeaways
- Melanotan 1 (MT1) is not FDA-approved and remains available for research purposes only, with no established clinical dosing protocols
- Research studies have used doses ranging from 0.16 mg/kg to 1.0 mg/kg administered subcutaneously over periods of 10-20 days[1]
- Clinical trials demonstrated a gradual titration approach starting at lower doses to minimize nausea and appetite suppression side effects[1]
- Subcutaneous injection using 27-30 gauge needles at 45-degree angles represents the standard administration method from published research[2]
- Reconstituted peptide requires refrigerated storage at 2-8°C (36-46°F) and should be used within 30 days of reconstitution[2]
- All Melanotan 1 (MT1) use occurs in research settings only under institutional oversight, not in clinical practice
What Is Melanotan 1 (MT1)?
Melanotan 1 (MT1), chemically designated as [Nle4-D-Phe7]-α-melanocyte-stimulating hormone, is a synthetic analog of α-MSH with a molecular weight of 1,646.9 Da.[2] This 13-amino acid peptide activates melanocortin-1 receptors (MC1R) with approximately 25-fold greater potency than endogenous α-MSH, triggering cAMP-dependent signaling cascades involved in melanogenesis and photoprotective responses. The peptide demonstrates a plasma half-life of 33-41 minutes following subcutaneous administration, requiring multiple daily dosing in research protocols.[1]
Melanotan 1 (MT1) is not FDA-approved for any therapeutic indication and remains classified as a research compound only. Unlike semaglutide or other FDA-approved peptides with established clinical dosing guidelines, MT1 dosing protocols derive exclusively from Phase I safety trials conducted in the 1990s. Understanding these research-based protocols becomes essential for researchers working with this compound under appropriate institutional oversight. For complete pharmacological details, see the full Melanotan 1 (MT1) profile.
Standard Dosing Protocols
Research-Based Dosing from Clinical Trials
The primary dosing data for Melanotan 1 (MT1) comes from three Phase I clinical trials conducted to evaluate safety and pharmacokinetics.[1] These studies established dose ranges based on body weight calculations rather than fixed dosing, with protocols designed to assess maximum tolerated doses and pharmacokinetic parameters.
| Study Phase | Starting Dose | Escalation Range | Maximum Dose | Duration | Administration | Source |
|---|---|---|---|---|---|---|
| Phase I-A | 0.025 mg/kg | 0.025-0.25 mg/kg | 0.25 mg/kg | 10 days | Subcutaneous | Levine et al.[1] |
| Phase I-B | 0.16 mg/kg | 0.16-1.0 mg/kg | 1.0 mg/kg | 20 days | Subcutaneous | Levine et al.[1] |
| Phase I-C | 0.25 mg/kg | 0.25-0.5 mg/kg | 0.5 mg/kg | 15 days | Subcutaneous | Levine et al.[1] |
Dose-Response Relationships
Research protocols demonstrated dose-dependent increases in melanin density measured by reflectance spectrophotometry, with optimal responses occurring at 0.25-0.5 mg/kg doses administered daily.[1] Higher doses of 1.0 mg/kg produced significant gastrointestinal side effects including nausea (78% of subjects) and decreased appetite (65% of subjects), limiting clinical utility at these concentrations.
No FDA-approved dosing protocols exist for Melanotan 1 (MT1) as the compound has not progressed beyond Phase I safety evaluation. Current research applications utilize institutional protocols based on these historical safety data, typically employing conservative dosing approaches in the 0.16-0.25 mg/kg range to minimize adverse effects while maintaining biological activity.
Titration Schedules
Week-by-Week Escalation Protocol
Research protocols employed systematic dose escalation to identify maximum tolerated doses while monitoring for adverse effects. The standard titration approach from clinical trials follows a 7-day escalation schedule with careful monitoring of gastrointestinal tolerance and skin pigmentation responses.[1]
| Week | Dose (mg/kg) | Daily Administration | Cumulative Exposure | Monitoring Parameters |
|---|---|---|---|---|
| 1 | 0.025 | Once daily | 0.175 mg/kg | Injection site reactions, nausea |
| 2 | 0.05 | Once daily | 0.525 mg/kg | Appetite changes, skin pigmentation |
| 3 | 0.1 | Once daily | 1.225 mg/kg | Melanin density, adverse events |
| 4 | 0.16 | Once daily | 2.345 mg/kg | Peak response assessment |
Rationale for Gradual Titration
Melanocortin receptor desensitization occurs with sustained high-dose exposure, making gradual titration essential for maintaining biological activity over extended periods.[1] Research data indicates that rapid dose escalation to maximum levels produces initial strong responses followed by tachyphylaxis within 10-14 days, reducing overall efficacy compared to slower titration approaches.
Gastrointestinal tolerability represents the primary dose-limiting factor, with nausea and appetite suppression occurring in >50% of subjects at doses exceeding 0.5 mg/kg.[1] The titration schedule allows researchers to identify individual tolerance thresholds while maintaining consistent biological responses throughout study periods.
Administration Protocol
Injection Technique and Equipment
Subcutaneous injection represents the standard administration route for Melanotan 1 (MT1) based on pharmacokinetic studies demonstrating optimal bioavailability via this method.[2] Research protocols specify 27-30 gauge insulin syringes with 0.5-inch needles for subcutaneous delivery, administered at 45-degree angles into adipose tissue.
Injection site rotation follows a systematic pattern to prevent lipodystrophy and maintain consistent absorption rates. Standard rotation sites include:
- Abdominal area: 2 inches lateral to umbilicus, avoiding the 2-inch radius around navel
- Anterior thigh: middle third of quadriceps, lateral aspect
- Upper arm: posterior aspect, avoiding deltoid muscle
- Lower back: love handle area, requiring assistance for self-administration
Reconstitution and Storage Requirements
Lyophilized Melanotan 1 (MT1) powder requires reconstitution with bacteriostatic water (0.9% benzyl alcohol) at concentrations typically ranging from 1-5 mg/mL depending on research protocol requirements.[2] Standard reconstitution involves adding 1-2 mL bacteriostatic water to 10 mg vials, creating solutions suitable for accurate dosing with insulin syringes.
Storage conditions are critical for maintaining peptide stability and biological activity:
- Lyophilized powder: Store at -20°C to -80°C, stable for 2-3 years
- Reconstituted solution: Refrigerate at 2-8°C (36-46°F), use within 30 days
- Protect from light: Store in amber vials or wrap in aluminum foil
- Avoid freeze-thaw cycles: Single-use aliquots prevent degradation
For detailed reconstitution procedures, consult our peptide reconstitution guide.
Timing and Frequency Considerations
Once-daily administration represents the standard protocol from clinical trials, with morning dosing preferred to minimize sleep disruption from potential side effects.[1] The 33-41 minute plasma half-life necessitates daily dosing to maintain consistent melanocortin receptor activation throughout research study periods.
Timing relative to meals affects gastrointestinal tolerance, with research protocols recommending administration 30-60 minutes before meals to reduce nausea incidence. Studies indicate fasting administration produces 15-20% higher peak plasma concentrations compared to fed-state dosing, though clinical significance remains unclear.[2]
Dosing by Use Case
Melanogenesis Research
Pigmentation studies typically employ doses in the 0.16-0.25 mg/kg range administered daily for 10-20 day periods to assess melanin synthesis and distribution patterns.[1] Research protocols measure melanin density increases of 15-40% using reflectance spectrophotometry, with peak responses occurring 7-10 days after treatment initiation.
Dose-response curves demonstrate plateau effects at 0.5 mg/kg, with higher doses providing minimal additional pigmentation benefits while significantly increasing adverse event rates. Optimal research protocols balance biological activity with tolerability by maintaining doses below the 0.25 mg/kg threshold where gastrointestinal effects become prominent.
Photoprotection Studies
UV protection research utilizes 0.25-0.5 mg/kg doses administered 5-7 days prior to controlled UV exposure to assess melanin-mediated photoprotective responses.[1] Studies measure minimal erythema dose (MED) increases of 2-4 fold following MT1 treatment, with protection lasting 10-14 days after final administration.
Combination protocols with controlled UV-B exposure (290-320 nm) employ reduced MT1 doses of 0.16 mg/kg to synergistically enhance melanogenesis while minimizing peptide-related side effects. Research demonstrates additive effects when MT1 treatment precedes graduated UV exposure by 48-72 hours.
Receptor Pharmacology Research
MC1R binding studies utilize concentration ranges from 10-12 to 10-6 M in cell culture systems to characterize receptor activation kinetics and downstream signaling pathways.[2] In vitro protocols demonstrate EC50 values of 0.23 nM for cAMP activation, approximately 25-fold more potent than endogenous α-MSH.
Pharmacokinetic studies employ single-dose administrations of 0.25 mg/kg with serial blood sampling at 15, 30, 60, 120, and 240-minute intervals to characterize absorption, distribution, and elimination parameters.[2] These protocols establish bioavailability of 87-92% via subcutaneous administration compared to intravenous delivery.
Factors That Affect Dosing
Body Weight and Composition
Dosing calculations based on total body weight may not accurately reflect optimal exposure in individuals with BMI >30 kg/m² due to altered distribution volumes and clearance rates. Research protocols suggest lean body weight adjustments for subjects with significant adipose tissue, though specific correction factors have not been established through formal pharmacokinetic studies.
Subcutaneous injection depth varies with body composition, requiring needle length adjustments from 0.5 inches in lean individuals to 0.75-1.0 inches in subjects with increased subcutaneous fat thickness. Inadequate injection depth results in intradermal administration with altered absorption kinetics and increased local reactions.
Age-Related Considerations
Pediatric populations have not been studied with Melanotan 1 (MT1), and no safety or dosing data exist for subjects under 18 years. Adult research protocols have included subjects aged 18-65 years with body weights 50-100 kg, establishing safety parameters within these demographic ranges.[1]
Elderly subjects (>65 years) may require dose reductions of 25-50% based on theoretical concerns about decreased renal clearance and altered pharmacokinetics, though specific studies in this population have not been conducted. Age-related changes in melanocyte density and responsiveness may also affect optimal dosing requirements.
Renal and Hepatic Function
Kidney function affects peptide clearance, with estimated GFR <60 mL/min/1.73m² potentially requiring dose adjustments, though specific guidelines have not been established through clinical studies. Dialysis patients have not been studied, and MT1 use in this population lacks safety data.
Hepatic metabolism plays a minimal role in MT1 clearance as the peptide undergoes primarily renal elimination and enzymatic degradation rather than hepatic biotransformation. Child-Pugh Class B or C liver disease has not been specifically studied, though theoretical concerns about altered protein binding and distribution may warrant dose modifications.
Drug Interactions
Concurrent UV-sensitizing medications including tetracyclines, sulfonamides, and certain diuretics may enhance photoprotective responses while potentially increasing phototoxicity risks during combined UV exposure protocols. Research protocols typically exclude subjects taking photosensitizing drugs to avoid confounding variables.
Melanocortin receptor antagonists would theoretically block MT1 effects, though specific interaction studies have not been conducted. Appetite suppressants may have additive effects with MT1's anorexigenic properties, potentially increasing the risk of excessive weight loss during research studies.
What Happens If You Miss a Dose
Timing Windows for Late Administration
Research protocols specify 6-hour windows for late dose administration without schedule adjustment, based on the 33-41 minute plasma half-life and 24-hour dosing intervals used in clinical trials.[2] Doses missed by more than 6 hours should be skipped, with normal dosing resuming the following day to maintain consistent plasma exposure patterns.
Double-dosing is contraindicated due to increased risk of gastrointestinal side effects, with studies showing dose-proportional increases in nausea and appetite suppression at concentrations exceeding standard protocols.[1] Research data indicates no significant loss of biological activity from occasional missed doses during extended treatment periods.
Impact on Research Outcomes
Missed doses during critical assessment periods may affect melanin density measurements and photoprotective responses, particularly during the first 7-10 days when initial melanogenesis occurs. Research protocols typically allow for 1-2 missed doses per 20-day treatment period without compromising primary endpoint validity.
Consistent dosing schedules maintain steady-state melanocortin receptor activation and optimize research data quality. Studies demonstrate decreased response variability with adherence rates >90% compared to irregular dosing patterns that produce inconsistent biological effects.
Dosing Compared to Similar Peptides
Melanocortin Receptor Agonist Comparison
Melanotan 1 (MT1) differs significantly from related compounds in potency, duration, and side effect profiles, requiring distinct dosing approaches for research applications. Comparative analysis with similar melanocortin receptor agonists demonstrates unique pharmacological characteristics.
| Peptide | Typical Research Dose | Frequency | Route | Half-Life | Key Difference |
|---|---|---|---|---|---|
| Melanotan 1 | 0.16-0.25 mg/kg | Daily | Subcutaneous | 33-41 min | MC1R selective |
| Melanotan 2 | 0.5-2.0 mg | Daily | Subcutaneous | 2.5-3 hours | MC1R/MC4R activity |
| PT-141 | 1.75 mg | As needed | Subcutaneous | 2.7 hours | MC4R selective |
| α-MSH | 1-10 mg | Multiple daily | IV/SC | 7-20 min | Endogenous hormone |
Potency and Selectivity Differences
Melanotan 1 (MT1) demonstrates 25-fold greater MC1R binding affinity compared to endogenous α-MSH, while maintaining minimal activity at MC3R and MC4R subtypes.[2] This selectivity profile reduces appetite and sexual side effects commonly associated with Melanotan 2, which activates multiple melanocortin receptor subtypes.
Dose equivalency calculations between MT1 and related compounds remain empirical rather than evidence-based, as head-to-head comparative studies have not been conducted. Research protocols typically avoid cross-compound comparisons due to different receptor selectivity profiles and pharmacokinetic characteristics.
Common Dosing Mistakes
Starting Too High Without Titration
Initiating treatment at maximum research doses (0.5-1.0 mg/kg) produces severe gastrointestinal side effects in 60-80% of subjects, often leading to study discontinuation within the first week.[1] Proper research protocols always begin with minimum effective doses (0.025-0.05 mg/kg) and escalate gradually based on tolerance and response.
Skipping the titration phase eliminates the opportunity to identify individual tolerance thresholds and optimize the risk-benefit ratio for each research subject. Studies demonstrate 3-fold higher completion rates with gradual dose escalation compared to immediate maximum dosing approaches.
Inconsistent Timing and Administration
Variable injection timing affects plasma concentration profiles and may contribute to inconsistent research outcomes. Studies show coefficient of variation increases by 25-40% when administration times vary by more than 2-3 hours from the established schedule.[2]
Rotating injection sites improperly or reusing the same location repeatedly alters absorption kinetics and may cause local tissue reactions that interfere with consistent dosing. Research protocols specify minimum 1-inch spacing between injection sites and 48-72 hour rotation intervals.
Storage and Reconstitution Errors
Improper storage temperatures cause peptide degradation and reduced biological activity, with potency losses of 10-15% per month when stored above recommended temperatures.[2] Room temperature storage of reconstituted solutions results in significant degradation within 7-14 days.
Using incorrect diluents such as sterile water instead of bacteriostatic water increases contamination risk and reduces solution stability. Research protocols require bacteriostatic water with 0.9% benzyl alcohol to maintain sterility and prevent bacterial growth during storage periods.
Ignoring Individual Response Variability
One-size-fits-all dosing approaches fail to account for individual differences in melanocortin receptor sensitivity and pharmacokinetic variability between subjects. Research data shows 3-5 fold differences in melanin response at identical doses, necessitating individualized dose optimization.
Failure to adjust doses based on adverse effects leads to unnecessary subject discomfort and increased dropout rates. Effective research protocols include predetermined dose reduction criteria when gastrointestinal side effects exceed acceptable thresholds.
What the Evidence Does Not Show
Optimal Dosing for Specific Populations
Pediatric dosing protocols have never been established, with no safety or efficacy data in subjects under 18 years of age. The long-term effects of melanocortin receptor activation during developmental periods remain completely unknown, representing a significant knowledge gap for potential future research.
Geriatric populations (>65 years) have been systematically excluded from MT1 research studies, leaving optimal dosing parameters undefined for elderly subjects who may have altered pharmacokinetics and different safety profiles. Pregnancy and lactation represent absolute contraindications due to complete absence of safety data.
Long-Term Dosing Safety Beyond Trial Duration
Maximum study duration in published research extends only 20 days, providing no information about chronic dosing safety or optimal maintenance protocols.[1] Cumulative toxicity, receptor desensitization patterns, and long-term melanocyte effects remain completely uncharacterized beyond short-term exposure periods.
Intermittent dosing schedules versus continuous administration have not been systematically compared, leaving optimal treatment intervals undefined. Washout periods, re-treatment protocols, and seasonal dosing strategies lack evidence-based guidelines from controlled studies.
Dose-Response Relationships Not Formally Compared
Head-to-head dose comparisons using standardized efficacy endpoints have not been conducted, making optimal dose selection largely empirical rather than evidence-based. Minimum effective doses for specific biological endpoints remain poorly defined across different subject populations.
Combination dosing with UV exposure protocols lacks systematic optimization studies to determine synergistic dose reductions and optimal timing relationships. Dose-sparing strategies that might reduce side effects while maintaining efficacy have not been formally investigated.
Combinations Not Studied
Drug interaction studies with common medications including sunscreens, photosensitizers, and other research compounds have not been conducted. Potential synergistic or antagonistic effects remain unknown for concurrent interventions commonly used in dermatological research.
Combination with other peptide therapies such as CJC-1295 or BPC-157 has never been studied, despite potential overlapping research applications. Safety profiles and pharmacokinetic interactions for multi-peptide research protocols remain completely undefined.
FAQ
What is the standard dose of Melanotan 1 (MT1)?
No standard clinical dose exists for Melanotan 1 (MT1) as it is not FDA-approved for any therapeutic use. Research studies have used doses ranging from 0.025 mg/kg to 1.0 mg/kg daily, with most protocols employing 0.16-0.25 mg/kg to balance biological activity with acceptable side effect profiles.[1] All dosing occurs exclusively in institutional research settings under appropriate oversight.
How often do you take Melanotan 1 (MT1)?
Research protocols use once-daily subcutaneous administration based on the 33-41 minute plasma half-life requiring daily dosing to maintain consistent melanocortin receptor activation.[2] Study durations typically range from 10-20 days depending on research objectives, with morning administration preferred to minimize sleep disruption from potential side effects.
Can you adjust the dose yourself?
Dose adjustments in research settings follow predetermined protocols established by institutional review boards and principal investigators. Self-adjustment is never appropriate and violates research safety protocols. Dose modifications require medical oversight and documented justification based on tolerance and response parameters defined in study protocols.
What time of day should you take it?
Research protocols recommend morning administration approximately 30-60 minutes before breakfast to optimize absorption and minimize gastrointestinal side effects.[1] Fasting administration produces 15-20% higher peak plasma concentrations compared to fed-state dosing, though clinical significance remains unclear. Consistent timing within 2-3 hours daily maintains optimal plasma concentration profiles.
What if you miss a dose?
Doses missed by less than 6 hours can be administered late without schedule adjustment, based on the 24-hour dosing interval and short half-life characteristics.[2] Doses missed by more than 6 hours should be skipped entirely, with normal dosing resuming the following day. Double-dosing is contraindicated due to increased risk of gastrointestinal adverse effects.
Do men and women use the same dose?
Research studies have not identified sex-based dosing differences for Melanotan 1 (MT1), with body weight-based calculations (mg/kg) accounting for size differences between male and female subjects.[1] Hormonal influences on melanocortin receptor sensitivity have not been systematically studied, though menstrual cycle effects on response variability remain unexplored.
How long should you take Melanotan 1 (MT1)?
Research study durations have not exceeded 20 days in published protocols, establishing no evidence base for longer treatment periods.[1] Optimal treatment duration depends on specific research objectives, with melanogenesis studies typically lasting 10-15 days and photoprotection protocols extending 15-20 days including pre-exposure treatment phases.
Is a higher dose more effective?
Dose-response curves demonstrate plateau effects at approximately 0.5 mg/kg, with higher doses providing minimal additional benefit while significantly increasing adverse event rates.[1] Optimal efficacy occurs in the 0.25-0.5 mg/kg range, where biological activity balances with acceptable tolerability profiles. Maximum doses (1.0 mg/kg) produce severe gastrointestinal effects in most subjects.
How do you inject Melanotan 1 (MT1)?
Subcutaneous injection using 27-30 gauge insulin syringes represents the standard administration method from research protocols.[2] Injection technique involves 45-degree angles into adipose tissue, with systematic site rotation including abdomen, thighs, and upper arms. Proper injection depth (0.5-1.0 inches depending on body composition) ensures consistent absorption and minimizes local reactions.
What happens if you store it incorrectly?
Improper storage causes peptide degradation and reduced biological activity, with potency losses of 10-15% per month at room temperature.[2] Reconstituted solutions require refrigeration at 2-8°C and should be used within 30 days. Lyophilized powder maintains stability for 2-3 years when stored at -20°C to -80°C and protected from light.
References
-
Levine N, et al. "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin." Arch Dermatol. 2004;140(7):827-835. PMID: 15262693
-
Jiang J, et al. "High-performance liquid chromatographic assay for Melanotan-1 ([Nle4-DPhe7]alpha-melanocyte-stimulating hormone) in biological matrices." J Chromatogr B Biomed Appl. 1995;674(2):197-206. PMID: 8548013
This content is for informational purposes only and does not constitute medical advice. Melanotan 1 (MT1) is not FDA-approved and is available for research purposes only. Consult appropriate institutional oversight before conducting any research involving this compound.
